We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Gastric Implant Aids Obese Patients

By HospiMedica staff writers
Posted on 11 Sep 2006
An improved gastric band helps morbidly obese patients achieve continued and sustained long-term weight loss without cutting, stapling, or intestinal re-routing, as is required with other weight-loss surgeries. More...


The Lap-Band advanced platform (AP) system has an adjustable gastric band, called Omniform, which offers a 360o inflation area that wraps uniformly around the stomach, minimizing the potential for crease-fold failure. The medical device is available in two size options to accommodate varying patient and surgical-technique requirements. The new design has attributes of the original Lap-Band system product line available since 1993 with nearly 300,000 gastric banding procedures performed worldwide.

During surgery with the Lap-Band system, surgeons use laparoscopic surgical techniques to implant an adjustable, reversible, inflatable band around the upper portion of the patient's stomach, which creates a small stomach pouch. The procedure results in weight loss by creating an earlier feeling of satiety and thus limiting or reducing food consumption. Based on global experience and clinical data, it has been demonstrated that patients who undergo the procedure experience a 55% average long-term weight loss. Additionally, an improvement in weight-related co-morbidities has been observed in these patients, including type II diabetes mellitus, dyslipidemia, sleep apnea, gastroesophageal reflux, hypertension, and asthma.

The Lap-Band System is the product of Allergan (Irvine, CA, USA)

"Adjustable gastric banding has provided bariatric surgeons with an effective, safe, and reversible weight-loss surgery option to treat their morbidly obese patients for more than a decade,” said Paul O'Brien, M.D. FRACS, director of the Centre of Obesity Research and Education at Monash University (Melbourne, Australia). "This latest advancement offers yet another safe, effective, and reversible weight-loss surgery solution to combat the global obesity epidemic.”



Related Links:
Allergan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
VTE Prevention System
Flowtron ACS900
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.